Full Text View
Tabular View
No Study Results Posted
Related Studies
Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by Erempharma.
Recruitment status was  Recruiting
Study NCT01288170   Information provided by Erempharma

First Received on February 1, 2011.   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cystic Fibrosis
Additional conditions recognized in this trial
Fibrosis
More general conditions related to this trial
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
Interventions listed in this trial
Nebcinal Tobi
Tobi Nebcinal
Sponsors listed in this trial
Erempharma
Hopitaux de Lyon
Clinical Investigation Center of Lyon


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services